Current Programs

Polpharma Biologics has a robust and expanding pipeline of biosimilars currently in development to treat a number of conditions across major therapeutic areas. Our proprietary cell line development platform and highly efficient R&D workflows have set the stage for the development of six biosimilar candidates, with one finished the phase III and second started the phase I of clinical trials. We are highly focused on advancing and expanding our product portfolio to increase patient access to these much-needed therapies and are open to partnering with other organizations to co-develop or commercialize our biosimilars.

 

Biosimilars Pipeline

Project
Originator
Therapeutic Area
Partner
Ranibizumab FYB201
Lucentis®
Ophthalmology
bioeq
Natalizumab PB006
Tysabri ®
Multiple Sclerosis
sandoz
Ustekinumab PB007
Stelara ®
Immunology
Vedolizumab PB016
Entyvio ®
Immunology
PB008
undisclosed
Oncology
PB014
undisclosed
Oncology
PB015
undisclosed
Oncology
Technical Development
Clinical Development
Submission
Partner
bioeq
sandoz

Biosimilars

Novel Biologics

Biosimilars

Capabilities

Leveraging our integrated capabilities and world-class facilities, Polpharma Biologics develops and manufactures our own high-quality biosimilars.